New data on the addition of Infinity Pharmaceuticals Inc.'s oral PI3K-gamma inhibitor, eganelisib, to PD-(L)1 in both urothelial and triple-negative breast cancer patients appeared to evidence benefits for the combination. Benefit for company shares (NASDAQ:INFI), however, was nowhere to be seen, as they fell 31.5% to $1.52 on July 27. In a same-day earnings report, the Cambridge, Mass.-based company said it had a cash balance of $97.3 million to fund further development of the drug and filed to raise the maximum amount of capital it may raise in future sales of its shares.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Allegro Ophthalmics, Cassava, Da Volterra, GNT, Inmune, Iveric, Lee's, Radius, Sorrento, Synaptogenix, Tarsus, Tonix, Virios.
TORONTO – What do ER doctors want most for their patients? Never to return to the ER, said Giovanni Ferrara, a professor at Edmonton’s University of Alberta Hospital's Division of Pulmonary Medicine. Ferrara is heading a feasibility project to see if a wearable device developed by Rochester, N.Y.-based Heath Care Originals Inc. can predict with scientific certainty when the condition of a patient with lung disease is worsening and requires another visit to the hospital.
The first COVID-19 patient has been enrolled the U.S. NIH’s ACTIV-4 Host Tissue trial, a study of four agents designed to fight dysregulation of the renin-angiotensin-aldosterone system and the immune system caused by a COVID-19 infection.
As amyotrophic lateral sclerosis continues to make headlines, candidates bearing varied approaches proliferate and the indication likely allows for multiple players, given the prospect of a combo regimen.
Shionogi & Co. Ltd. started a phase I trial in Japan for S-217622, its orally administered 3CL protease inhibitor for treating COVID-19. Should the drug be approved by Japanese regulators, it would be the first Japanese-developed COVID-19 treatment to be approved in the country.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abeona, Acticor, Adverum, Aurion, Denali, F-star, Immunicum, Innovent, Kyowa Kirin, Mediwound, NGM, Synlogic.
PARIS – Royal Philips NV is working with the Spanish National Center for Cardiovascular Research (CNIC) on an ultrafast cardiac magnetic resonance imaging (MRI) protocol that could reduce scanning times to just a few minutes.
LONDON – An attempt to develop an alternative sampling method to replace unpleasant nasopharyngeal swabbing in COVID-19 diagnosis has failed, with researchers at Owlstone Medical Ltd. finding the number of viral particles that can be collected from the breath of hospitalized patients is below the limit of detection. Owlstone is a specialist in collecting and analyzing breath samples to look for volatile organic compounds that are biomarkers of disease, such as lung cancer and asthma.
Alzamend Neuro Inc.’s positive preclinical data for AL-002 sent the company’s stock (NADAQ:ALZN) more than 70% higher before the market opened July 23. The Tampa, Fla.-based biopharma is researching a mutant-peptide sensitized cell for treating Alzheimer’s disease. The positive data came from a GLP toxicology study using a transgenic mouse model.
RSS
